The 8 analysts offering 12-month price forecasts for Sutro Biopharma Inc have a median target of 19.50, with a high estimate of 23.00 and a low estimate of 16.00. The median estimate represents a +73.95% increase from the last price of 11.21.
The current consensus among 9 polled investment analysts is to Buy stock in Sutro Biopharma Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.55
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.